Taking this deeper into the HAVCR2-MSLN relationship, RNA-interference therapies have also been used in combination with CAR-T approaches to first knock down HAVCR2/TIM3 expression and enhance the cytotoxic functioning and proliferation capacity of therapeutic CAR-T cells in numerous in vitro cancer models [49]. The gene discussed is HAVCR2; the disease is cancer.